Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Mersana Therapeutics initiates expansion portion of UPGRADE-A trial » 08:04
02/01/23
02/01
08:04
02/01/23
08:04
MRSN

Mersana Therapeutics

$6.57 /

+0.05 (+0.77%)

Mersana Therapeutics…

Mersana Therapeutics announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in platinum-sensitive ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload designed to enable a high drug-to-antibody ratio and controlled bystander effect. "While the combination of carboplatin and paclitaxel has historically served as the standard of care in early lines of therapy for platinum-sensitive ovarian cancer, it is limited by distinct tolerability and side effect challenges that can include severe neutropenia, peripheral neuropathy and alopecia," said Dr. Arvin Yang, Senior Vice President and Chief Medical Officer of Mersana Therapeutics. "With UPGRADE-A, we are investigating the potential benefits of replacing paclitaxel with UpRi in the induction phase of treatment and then continuing UpRi as maintenance monotherapy. We are pleased to enter this exciting new phase of the trial." Mersana expects to report interim data from UPGRADE-A in the second half of 2023.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$6.57 /

+0.05 (+0.77%)

MRSN Mersana Therapeutics
$6.57 /

+0.05 (+0.77%)

01/20/23 Citi
Mersana Therapeutics initiated with a Buy at Citi
11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
MRSN Mersana Therapeutics
$6.57 /

+0.05 (+0.77%)

MRSN Mersana Therapeutics
$6.57 /

+0.05 (+0.77%)

Over a week ago
Hot Stocks
Mersana Therapeutics initiates Phase 1 trial of XMT-2056 » 08:08
01/25/23
01/25
08:08
01/25/23
08:08
MRSN

Mersana Therapeutics

$6.63 /

+0.105 (+1.61%)

Mersana Therapeutics…

Mersana Therapeutics announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company's lead Immunosynthen product candidate. "We believe this trial will give us important insights into XMT-2056's tolerability and clinical activity profile across a range of solid tumors while also helping to demonstrate the differentiated nature of our Immunosynthen platform, which is designed to take ADCs beyond the cytotoxic realm by enabling innate immune activation," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "Given the preclinical activity XMT-2056 has demonstrated as a monotherapy and in combination with multiple agents, including standard-of-care HER2 therapies, we believe XMT-2056 may offer a differentiated and highly complementary therapeutic approach. We are excited to have candidates derived from all three of our ADC platforms in active clinical trials, demonstrating our continued innovation and leadership within the ADC space."

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$6.63 /

+0.105 (+1.61%)

MRSN Mersana Therapeutics
$6.63 /

+0.105 (+1.61%)

01/20/23 Citi
Mersana Therapeutics initiated with a Buy at Citi
11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
MRSN Mersana Therapeutics
$6.63 /

+0.105 (+1.61%)

MRSN Mersana Therapeutics
$6.63 /

+0.105 (+1.61%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:44
01/20/23
01/20
09:44
01/20/23
09:44
DOMO

Domo

$12.86 /

-0.01 (-0.08%)

, PD

PagerDuty

$26.37 /

+ (+0.00%)

, REGN

Regeneron

$715.60 /

-3.365 (-0.47%)

, RL

Ralph Lauren

$117.33 /

+ (+0.00%)

, QSR

Restaurant Brands

$65.61 /

+0.06 (+0.09%)

, CRM

Salesforce

$146.44 /

-0.01 (-0.01%)

, MOS

Mosaic

$46.72 /

-0.005 (-0.01%)

, PINS

Pinterest

$26.77 /

+ (+0.00%)

, SQSP

Squarespace

$22.94 /

+0.015 (+0.07%)

, W

Wayfair

$38.91 /

+ (+0.00%)

, PARR

Par Pacific

$24.53 /

-0.02 (-0.08%)

, MRSN

Mersana Therapeutics

$5.83 /

+0.005 (+0.09%)

, MRNS

Marinus Pharmaceuticals

$5.20 /

+ (+0.00%)

, WRB

W. R. Berkley

$69.83 /

+ (+0.00%)

Institutional investors…

ShowHide Related Items >><<
WRB W. R. Berkley
$69.83 /

+ (+0.00%)

W Wayfair
$38.91 /

+ (+0.00%)

SQSP Squarespace
$22.94 /

+0.015 (+0.07%)

RL Ralph Lauren
$117.33 /

+ (+0.00%)

REGN Regeneron
$715.60 /

-3.365 (-0.47%)

QSR Restaurant Brands
$65.61 /

+0.06 (+0.09%)

PINS Pinterest
$26.77 /

+ (+0.00%)

PD PagerDuty
$26.37 /

+ (+0.00%)

PARR Par Pacific
$24.53 /

-0.02 (-0.08%)

MRSN Mersana Therapeutics
$5.83 /

+0.005 (+0.09%)

MRNS Marinus Pharmaceuticals
$5.20 /

+ (+0.00%)

MOS Mosaic
$46.72 /

-0.005 (-0.01%)

DOMO Domo
$12.86 /

-0.01 (-0.08%)

CRM Salesforce
$146.44 /

-0.01 (-0.01%)

DOMO Domo
$12.86 /

-0.01 (-0.08%)

01/20/23 Morgan Stanley
Domo downgraded to Equal Weight from Overweight at Morgan Stanley
12/09/22 Lake Street
Domo price target lowered to $23 from $25 at Lake Street
12/09/22 Morgan Stanley
Domo price target lowered to $51 from $56 at Morgan Stanley
12/09/22 Cowen
Domo price target lowered to $23 from $27 at Cowen
PD PagerDuty
$26.37 /

+ (+0.00%)

01/20/23 Morgan Stanley
PagerDuty upgraded to Overweight from Equal Weight at Morgan Stanley
12/02/22 Canaccord
PagerDuty price target lowered to $31 from $32 at Canaccord
12/02/22 Baird
PagerDuty price target lowered to $32 from $35 at Baird
10/26/22 Truist
PagerDuty price target lowered to $30 from $35 at Truist
REGN Regeneron
$715.60 /

-3.365 (-0.47%)

01/20/23 JPMorgan
Regeneron upgraded to Overweight from Neutral at JPMorgan
01/09/23 Piper Sandler
Piper 'at a loss' to explain Regeneron Q4 miss for Eylea
12/30/22 Oppenheimer
Opco reveals three biotech stocks that will outperform in 2023
11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
RL Ralph Lauren
$117.33 /

+ (+0.00%)

01/20/23 Barclays
Ralph Lauren upgraded to Overweight from Equal Weight at Barclays
12/12/22 Cowen
Ralph Lauren price target raised to $148 from $132 at Cowen
11/29/22 JPMorgan
Ralph Lauren price target raised to $132 from $127 at JPMorgan
11/11/22 UBS
Ralph Lauren price target raised to $130 from $128 at UBS
QSR Restaurant Brands
$65.61 /

+0.06 (+0.09%)

01/19/23 BMO Capital
Restaurant Brands upgraded to Outperform from Market Perform at BMO Capital
01/18/23 Cowen
Restaurant Brands price target raised to $72 from $63 at Cowen
01/05/23 Oppenheimer
Oppenheimer downgrades Wendy's, reveals top 2023 restaurant picks
01/05/23 Barclays
Restaurant Brands price target raised to $80 from $68 at Barclays
CRM Salesforce
$146.44 /

-0.01 (-0.01%)

01/20/23 Cowen
Salesforce downgraded to Market Perform at Cowen with disruption risk elevated
01/20/23 Cowen
Salesforce downgraded to Market Perform from Outperform at Cowen
01/17/23 DA Davidson
Salesforce initiated with a Neutral at DA Davidson
01/13/23 Atlantic Equities
Salesforce downgraded to Neutral from Overweight at Atlantic Equities
MOS Mosaic
$46.72 /

-0.005 (-0.01%)

01/20/23 Citi
Mosaic downgraded to Neutral from Buy at Citi
01/18/23 Wells Fargo
Mosaic initiated with an Equal Weight at Wells Fargo
01/18/23 Wells Fargo
Mosaic initiated with an Equal Weight at Wells Fargo
01/13/23 Exane BNP Paribas
Mosaic downgraded to Underperform from Neutral at Exane BNP Paribas
PINS Pinterest
$26.77 /

+ (+0.00%)

01/20/23 MKM Partners
MKM Partners cuts Pinterest to Neutral, sees balanced risk-reward
01/20/23 MKM Partners
Pinterest downgraded to Neutral from Buy at MKM Partners
01/19/23 JPMorgan
JPMorgan calls out Meta as top pick ahead of earnings from online ads group
12/13/22 Piper Sandler
Pinterest upgraded to Overweight from Neutral at Piper Sandler
SQSP Squarespace
$22.94 /

+0.015 (+0.07%)

01/20/23 KeyBanc
Squarespace downgraded to Sector Weight from Overweight at KeyBanc
01/05/23 Wolfe Research
Squarespace initiated with a Peer Perform at Wolfe Research
12/13/22 Citi
Squarespace transferred with a Neutral at Citi
11/21/22 Piper Sandler
Squarespace upgraded to Overweight from Neutral at Piper Sandler
W Wayfair
$38.91 /

+ (+0.00%)

01/20/23 KeyBanc
Wayfair initiated with a Sector Weight at KeyBanc
01/17/23 Morgan Stanley
Wayfair upgraded to Equal Weight from Underweight at Morgan Stanley
01/05/23 Wells Fargo
Wayfair price target lowered to $30 from $35 at Wells Fargo
12/15/22 Wolfe Research
Wayfair initiated with a Peer Perform at Wolfe Research
PARR Par Pacific
$24.53 /

-0.02 (-0.08%)

01/20/23 Piper Sandler
Par Pacific upgraded to Overweight from Neutral at Piper Sandler
12/19/22 Piper Sandler
Par Pacific price target lowered to $27 from $29 at Piper Sandler
11/09/22 Piper Sandler
Par Pacific price target raised to $29 from $22 at Piper Sandler
10/24/22 Cowen
Par Pacific price target raised to $28 from $21 at Cowen
MRSN Mersana Therapeutics
$5.83 /

+0.005 (+0.09%)

01/20/23 Citi
Mersana Therapeutics initiated with a Buy at Citi
11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
MRNS Marinus Pharmaceuticals
$5.20 /

+ (+0.00%)

01/20/23 RBC Capital
Marinus Pharmaceuticals initiated with an Outperform at RBC Capital
11/09/22 Baird
Marinus Pharmaceuticals price target lowered to $24 from $32 at Baird
11/09/22 H.C. Wainwright
Marinus Pharmaceuticals price target lowered to $27 from $38 at H.C. Wainwright
04/20/22 Cantor Fitzgerald
Marinus Pharmaceuticals price target raised to $28 from $25 at Cantor Fitzgerald
WRB W. R. Berkley
$69.83 /

+ (+0.00%)

01/19/23 BMO Capital
W. R. Berkley initiated with a Market Perform at BMO Capital
01/10/23 Evercore ISI
Hartford downgraded at Evercore ISI, more relative upside seen elsewhere
11/11/22 Janney Montgomery Scott
Janney starts W. R. Berkley with a Buy, $88 fair value estimate
11/11/22 Janney Montgomery Scott
W. R. Berkley initiated with a Buy at Janney Montgomery Scott
WRB W. R. Berkley
$69.83 /

+ (+0.00%)

W Wayfair
$38.91 /

+ (+0.00%)

SQSP Squarespace
$22.94 /

+0.015 (+0.07%)

RL Ralph Lauren
$117.33 /

+ (+0.00%)

REGN Regeneron
$715.60 /

-3.365 (-0.47%)

QSR Restaurant Brands
$65.61 /

+0.06 (+0.09%)

PINS Pinterest
$26.77 /

+ (+0.00%)

PD PagerDuty
$26.37 /

+ (+0.00%)

PARR Par Pacific
$24.53 /

-0.02 (-0.08%)

MRSN Mersana Therapeutics
$5.83 /

+0.005 (+0.09%)

MRNS Marinus Pharmaceuticals
$5.20 /

+ (+0.00%)

MOS Mosaic
$46.72 /

-0.005 (-0.01%)

DOMO Domo
$12.86 /

-0.01 (-0.08%)

CRM Salesforce
$146.44 /

-0.01 (-0.01%)

  • 08
    Nov
W Wayfair
$38.91 /

+ (+0.00%)

REGN Regeneron
$715.60 /

-3.365 (-0.47%)

QSR Restaurant Brands
$65.61 /

+0.06 (+0.09%)

PINS Pinterest
$26.77 /

+ (+0.00%)

CRM Salesforce
$146.44 /

-0.01 (-0.01%)

WRB W. R. Berkley
$69.83 /

+ (+0.00%)

W Wayfair
$38.91 /

+ (+0.00%)

SQSP Squarespace
$22.94 /

+0.015 (+0.07%)

RL Ralph Lauren
$117.33 /

+ (+0.00%)

REGN Regeneron
$715.60 /

-3.365 (-0.47%)

QSR Restaurant Brands
$65.61 /

+0.06 (+0.09%)

PINS Pinterest
$26.77 /

+ (+0.00%)

PD PagerDuty
$26.37 /

+ (+0.00%)

MRSN Mersana Therapeutics
$5.83 /

+0.005 (+0.09%)

MOS Mosaic
$46.72 /

-0.005 (-0.01%)

DOMO Domo
$12.86 /

-0.01 (-0.08%)

CRM Salesforce
$146.44 /

-0.01 (-0.01%)

W Wayfair
$38.91 /

+ (+0.00%)

RL Ralph Lauren
$117.33 /

+ (+0.00%)

REGN Regeneron
$715.60 /

-3.365 (-0.47%)

QSR Restaurant Brands
$65.61 /

+0.06 (+0.09%)

PINS Pinterest
$26.77 /

+ (+0.00%)

PARR Par Pacific
$24.53 /

-0.02 (-0.08%)

MOS Mosaic
$46.72 /

-0.005 (-0.01%)

CRM Salesforce
$146.44 /

-0.01 (-0.01%)

Initiation
Mersana Therapeutics initiated with a Buy at Citi » 07:21
01/20/23
01/20
07:21
01/20/23
07:21
MRSN

Mersana Therapeutics

$5.83 /

+0.185 (+3.28%)

Citi analyst Ashiq…

Citi analyst Ashiq Mubarack initiated coverage of Mersana Therapeutics with a Buy rating and $12 price target. He believes topline registrational data from the UPLIFT Phase 2 study evaluating upifitamab rilsodotin in platinum-resistant ovarian cancer, or PROC, will be "a catalyst of significant debate" over the next roughly six months, Mubarack tells investors. While he acknowledges the readout will be binary, he thinks investors are underappreciating UPLIFT's probability of success. If UPLIFT is positive, he thinks shares could trade up to 100% above current levels given such a result will leave Mersana with "a clear pathway to an accelerated approval filing" by year end, the analyst added.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$5.83 /

+0.185 (+3.28%)

MRSN Mersana Therapeutics
$5.83 /

+0.185 (+3.28%)

11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
MRSN Mersana Therapeutics
$5.83 /

+0.185 (+3.28%)

MRSN Mersana Therapeutics
$5.83 /

+0.185 (+3.28%)

Hot Stocks
Mersana Therapeutics provides business update, expected milestones » 07:04
01/06/23
01/06
07:04
01/06/23
07:04
MRSN

Mersana Therapeutics

$5.27 /

-0.13 (-2.41%)

Mersana Therapeutics…

Mersana Therapeutics provided a business update and announced strategic objectives and expected milestones for 2023. "Following a year of tremendous accomplishment in 2022, we are now approaching top-line data from our first registrational trial of UpRi, which we believe will provide an opportunity to further demonstrate Mersana's increasing role as an ADC leader," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "The data we expect to report from our UPLIFT clinical trial in mid-2023 will represent the most significant milestone to date in our effort to establish UpRi as a foundational medicine for patients with ovarian cancer. Assuming positive data, we plan to target the submission of a BLA around the end of 2023 and prepare for a potential U.S. commercial launch in 2024. We will also continue to advance our UP-NEXT and UPGRADE-A trials of UpRi in earlier lines of treatment." Strategic Objective: Establish UpRi as a Foundational Medicine in Ovarian Cancer - Expected Milestones: Report top-line data from UPLIFT in mid-2023; Assuming positive data, submit a biologics license application to the U.S. Food and Drug Administration around the end of 2023; Prepare for potential U.S. accelerated approval and commercial launch in 2024; Significantly advance enrollment of UP-NEXT in 2023; and Initiate dose expansion portion of UPGRADE-A in the first quarter of 2023 and report interim data from UPGRADE-A in the second half of 2023. Strategic Objective: Advance Clinical-Stage Pipeline - expected Milestones: XMT-1660: Complete dose escalation portion of Phase 1 clinical trial in 2023; XMT-2056: Initiate Phase 1 clinical trial in the first quarter of 2023. Strategic Objective: Position Mersana as the ADC Partner-of-Choice - Expected Milestones: Pursue impactful new collaborations; Execute against existing collaboration agreements;.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$5.27 /

-0.13 (-2.41%)

MRSN Mersana Therapeutics
$5.27 /

-0.13 (-2.41%)

11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
MRSN Mersana Therapeutics
$5.27 /

-0.13 (-2.41%)

MRSN Mersana Therapeutics
$5.27 /

-0.13 (-2.41%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 18:35
12/22/22
12/22
18:35
12/22/22
18:35
XPON

Expion360

/

+

, OWLT

Owlet

/

+

, TSLA

Tesla

$125.34 /

-12.0899 (-8.80%)

, MRSN

Mersana Therapeutics

$5.98 /

-0.06 (-0.99%)

, AVO

Mission Produce

$14.60 /

-0.385 (-2.57%)

, LMNR

Limoneira

$13.34 /

+0.03 (+0.23%)

Check out this evening's…

ShowHide Related Items >><<
XPON Expion360
/

+

TSLA Tesla
$125.34 /

-12.0899 (-8.80%)

OWLT Owlet
/

+

MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

LMNR Limoneira
$13.34 /

+0.03 (+0.23%)

AVO Mission Produce
$14.60 /

-0.385 (-2.57%)

XPON Expion360
/

+

OWLT Owlet
/

+

11/16/22 Citi
Owlet price target lowered to $1 from $2.25 at Citi
10/20/22 Cowen
Owlet price target lowered to $4 from $5 at Cowen
09/30/22 BofA
Owlet initiated with a Neutral at BofA
05/12/22 Citi
Owlet price target raised to $3.25 from $2.50 at Citi
TSLA Tesla
$125.34 /

-12.0899 (-8.80%)

12/22/22 Canaccord
Tesla price target lowered to $275 from $304 at Canaccord
12/21/22 Morgan Stanley
Tesla shedding $600B of value presents buying opportunity, says Morgan Stanley
12/21/22 Deutsche Bank
Tesla price target lowered to $270 from $355 at Deutsche Bank
12/20/22 Evercore ISI
Tesla price target lowered to $200 from $300 at Evercore ISI
MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
AVO Mission Produce
$14.60 /

-0.385 (-2.57%)

04/07/22 Citi
Mission Produce upgraded to Buy from Neutral at Citi
12/23/21 Stephens
Mission Produce price target lowered to $20 from $25 at Stephens
LMNR Limoneira
$13.34 /

+0.03 (+0.23%)

06/08/22 Lake Street
Limoneira Q2 'most encouraging quarter in a year,' says Lake Street
03/11/22 Lake Street
Limoneira price target lowered to $19 from $23 at Lake Street
XPON Expion360
/

+

TSLA Tesla
$125.34 /

-12.0899 (-8.80%)

OWLT Owlet
/

+

MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

LMNR Limoneira
$13.34 /

+0.03 (+0.23%)

AVO Mission Produce
$14.60 /

-0.385 (-2.57%)

  • 01
    Apr
TSLA Tesla
$125.34 /

-12.0899 (-8.80%)

TSLA Tesla
$125.34 /

-12.0899 (-8.80%)

MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

LMNR Limoneira
$13.34 /

+0.03 (+0.23%)

TSLA Tesla
$125.34 /

-12.0899 (-8.80%)

Hot Stocks
Mersana reports research collaboration, commercial license pact with Merck KGaA » 16:18
12/22/22
12/22
16:18
12/22/22
16:18
MRSN

Mersana Therapeutics

$5.98 /

-0.06 (-0.99%)

, MKGAY

Merck KGaA

$38.36 /

+ (+0.00%)

Mersana Therapeutics…

Mersana Therapeutics (MRSN) announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets. Immunosynthen, Mersana's proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both tumor-resident immune cells and in antigen-expressing tumor cells. "Building on our deep expertise in the ADC space, we are focused on the discovery of next-generation state-of-the-art ADC drugs," said Paul Lyne, Head of Research Unit, Oncology, Merck KGaA, Darmstadt, Germany. "An approach that can directly target the tumor microenvironment with an immunomodulatory ADC has the potential to bring the benefits of this immunotherapy to a broader group of patients. This collaboration with Mersana to design novel immunostimulatory ADCs that can harness the potential of the STING pathway is an ideal complement to our innovation." Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilizing its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, Germany. Mersana will be responsible for certain discovery activities, as well as limited preclinical manufacturing and supply obligations, which will be reimbursed by Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany will be solely responsible for in vitro and in vivo characterization, other preclinical work, and all clinical development and potential commercialization activities relating to any resulting product candidates. Mersana will receive an upfront payment of $30M. Mersana is also eligible to receive reimbursement of certain costs, up to $800M in potential regulatory, development and commercial milestone payments, and tiered royalties up to the low double-digit percentages on worldwide net sales of any approved ADCs developed under the agreement.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
MKGAY Merck KGaA
$38.36 /

+ (+0.00%)

12/14/22 UBS
Merck KGaA upgraded to Buy from Neutral at UBS
11/14/22 BofA
Merck KGaA upgraded to Buy from Neutral at BofA
07/25/22 Jefferies
Merck KGaA initiated with a Buy at Jefferies
03/14/22 JPMorgan
Merck KGaA price target lowered to EUR 250 from EUR 270 at JPMorgan
MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

MRSN Mersana Therapeutics
$5.98 /

-0.06 (-0.99%)

Hot Stocks
Mersana Therapeutics announces E.C. designated UpRi Orphan Medicinal product » 08:20
12/14/22
12/14
08:20
12/14/22
08:20
MRSN

Mersana Therapeutics

$7.03 /

+0.28 (+4.15%)

Mersana Therapeutics…

Mersana Therapeutics announced that the European Commission, E.C., has designated upifitamab rilsodotin, UpRi, as an orphan medicinal product for the treatment of ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that is designed to enable a high drug-to-antibody ratio and controlled bystander effect. "Receiving this orphan designation in the European Union is an important regulatory milestone for Mersana as we seek to expedite UpRi's global development," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "This designation reinforces the unmet needs that patients with ovarian cancer continue to face today. We look forward to advancing our ongoing clinical trials, which aim to establish UpRi as a foundational medicine in ovarian cancer."

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$7.03 /

+0.28 (+4.15%)

MRSN Mersana Therapeutics
$7.03 /

+0.28 (+4.15%)

11/21/22 Truist
Truist starts Mersana Therapeutics at Buy on 'differentiating' components
11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
MRSN Mersana Therapeutics
$7.03 /

+0.28 (+4.15%)

MRSN Mersana Therapeutics
$7.03 /

+0.28 (+4.15%)

Initiation
Truist starts Mersana Therapeutics at Buy on 'differentiating' components » 07:49
11/21/22
11/21
07:49
11/21/22
07:49
MRSN

Mersana Therapeutics

$6.37 /

-0.155 (-2.38%)

Truist analyst Asthika…

Truist analyst Asthika Goonewarden initiated coverage of Mersana Therapeutics with a Buy rating and $12 price target. While the company is a newer entrant to the antibody drug conjugate space, it has several proprietary components that he finds "very attractive and differentiating", the analyst tells investors in a research note. Goonewarden adds that given a pivotal study for their lead candidate UpRi being underway, along with two new ADCs entering the clinic, he expects mid-2023 and the second half of 2023 to be "quite active" for Mersana Therapeutics.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

11/21/22 Truist
Mersana Therapeutics initiated with a Buy at Truist
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
05/09/22 H.C. Wainwright
Mersana price target lowered to $19 from $24 at H.C. Wainwright
MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

Initiation
Mersana Therapeutics initiated with a Buy at Truist » 06:29
11/21/22
11/21
06:29
11/21/22
06:29
MRSN

Mersana Therapeutics

$6.37 /

-0.155 (-2.38%)

Truist analyst Asthika…

Truist analyst Asthika Goonewarden initiated coverage of Mersana Therapeutics with a Buy rating and $12 price target.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
05/09/22 H.C. Wainwright
Mersana price target lowered to $19 from $24 at H.C. Wainwright
MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

MRSN Mersana Therapeutics
$6.37 /

-0.155 (-2.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.